Researchers from KAUST, King Faisal Specialist Hospital, and collaborators have developed a new method to predict cardiometabolic disease risk in underrepresented ethnic populations using genetic information and public databases. The study focused on Arab communities and created a framework to determine polygenic scores for more accurate heart disease prediction. The framework was validated using records of over 5,000 Arab patients, demonstrating that genetic risk complements conventional risk factors. Why it matters: This research addresses a critical gap in genomic data for non-European populations, potentially leading to more effective and personalized healthcare strategies in the Arab world and beyond.
Researchers at Khalifa University have developed an AI system capable of predicting cardiovascular disease (CVD) risks up to 12 years in advance. The AI model uses data from the Framingham Heart Study to assess long-term CVD risk factors. It outperforms existing methods in predicting CVD incidence over extended periods. Why it matters: This advancement could significantly improve preventative healthcare strategies in the UAE and globally by enabling earlier interventions for individuals at high risk of heart disease.
MBZUAI researchers co-led a study published in Nature demonstrating that GluFormer, an AI foundation model trained on continuous glucose monitoring (CGM) data, more accurately predicts long-term diabetes and cardiovascular risk than current clinical standards. GluFormer, built on a transformer architecture and trained using NVIDIA AI infrastructure on over 10 million CGM measurements, forecasts individual health risks using short-term glucose dynamics. In a 12-year follow-up, the model captured 66% of new-onset diabetes cases and 69% of cardiovascular-death events in its highest-risk group, outperforming established CGM-derived metrics across 19 external cohorts. Why it matters: The development of GluFormer represents a significant advancement in personalized healthcare, enabling proactive and individualized health strategies through the analysis of dynamic glucose data.
MBZUAI alumnus Ikboljon Sobirov is using AI to develop new diagnostic tools for cardiovascular disease at the University of Oxford. His research focuses on building imaging biomarkers by integrating transcriptomic data with medical scans. The goal is to predict how a patient will respond to specific medications using only images. Why it matters: This work showcases the potential of AI and multi-modal data to personalize medicine and improve healthcare outcomes in the region and globally.